(Q38246002)

English

The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management

scientific article published on 03 September 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 August 2017

The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management (English)

1 reference

Europe PubMed Central

31 August 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

acute coronary syndrome

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25187508%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Pamela Katz

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25187508%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Lawrence A Leiter

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25187508%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Lars Rydén

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25187508%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

0 references

publication date

3 September 2014

1 reference

Europe PubMed Central

31 August 2017

Diabetes and Vascular Disease Research

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25187508%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25187508%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25187508%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

395-409

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25187508%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Secular changes in cardiovascular risk factors and attack rate of myocardial infarction among men aged 50 in Gothenburg, Sweden. Accurate prediction using risk models

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Fasting glucose levels within the high normal range predict cardiovascular outcome

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary).

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Glycation and insulin resistance: novel mechanisms and unique targets?

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Adhesion molecules and atherosclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Role of adipose tissue in haemostasis, coagulation and fibrinolysis.

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Susceptibility of LDL and its subfractions to glycation

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Antiinflammatory properties of HDL.

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Lipid parameters for measuring risk of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart.

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey.

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Standards of medical care in diabetes--2013

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Oral glucose tolerance test and HbA₁c for diagnosis of diabetes in patients undergoing coronary angiography: [corrected] the Silent Diabetes Study.

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes.

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism.

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Associati

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics.

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Current concepts on coronary revascularization in diabetic patients

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Strategies for multivessel revascularization in patients with diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Coronary artery bypass surgery provides long-term results superior to percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Effect of a multifactorial intervention on mortality in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by rep

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

We've come a long way…haven't we?

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Basal insulin and cardiovascular and other outcomes in dysglycemia

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Pharmacological management of type 2 diabetes: the potential of incretin-based therapies

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

The forgotten majority: unfinished business in cardiovascular risk reduction

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Effects of combination lipid therapy in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Effects of torcetrapib in patients at high risk for coronary events

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Effects of dalcetrapib in patients with a recent acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Outcome of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus (a SORT OUT III Substudy)

1 reference

https://api.crossref.org/works/10.1177%2F1479164114546854

21 January 2018

Identifiers

10.1177/1479164114546854

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25187508%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25187508%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38246002&oldid=1749091146"